Home Tags STRO-001

Tag: STRO-001

The sign I Amsterdam in front of rijksmuseum in Amsterdam, The Netherlands.

Sutro Presents Preliminary Results From Ongoing Phase I Study of STRO-001

California-based Sutro Biopharma has confirmed that the company will present preliminary results from the first 14 patients enrolled in the company's ongoing Phase I...

Sutro Confirms IND for Second Cell-Free ADC Targeting Anti-Folate Receptor-α for...

Sutro Biopharma confirmed that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for...

A New Generation of Precisely Engineered CD74-Targeting ADCs Receive Orphan Drug...

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for STRO-001 for the treatment of multiple myeloma (MM).In the United States,...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Sutro Partners with The Leukemia & Lymphoma Society to Develop STRO-001

Earlier today Sutro Biopharma, a clinical-stage drug discovery, development and manufacturing company, and The Leukemia & Lymphoma Society®, the world's largest voluntary health agency...

First Clinical Trial of STRO-001 Targeting CD74 to Treat Lymphoma and...

Researchers have begun dosing patients in its initial clinical trial of a new generation of precisely engineered - first-in-class - antibody-drug conjugate, or ADC,...

Sutro BioPharma and Celgene Refocus Immuno-Oncology Collaboration – Rapidly Advance Promising...

Earlier today Sutro Biopharma and Celgene confirmed that the companies decided to refocusing the 2014 immuno-oncology collaboration with on four programs that are advancing...

Data Confirms STRO-001 Eradicates B-Cell Hematologic Malignancies and Prolongs Survival

STRO-001, an antibody-drug conjugate or ADC targeting the CD74 cell surface protein in hematologic B-cell malignancies, being developed by Sutro Biopharma, has shown to...

Antibody-drug Conjugate Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant...

Sutro Biopharma, a biotechnology company developing best-in-class antibody drug conjugate (ADC) and multi-specific antibody-based therapeutics for cancer therapy, including immune-oncology therapies has launched IND-enabling studies, including...